Appropriateness of the prescriptions of conventional versus new oral anticoagulants at discharge from a department of internal medicine

被引:3
作者
Bochatay, L. [1 ]
Beney, J. [1 ]
Jordan-von Gunten, V. [1 ]
Petignat, P. A. [2 ]
Roulet, L. [1 ]
机构
[1] Hop Valais, Inst Cent ICHV, Serv Pharm, Ave Grand Champsec 86, CH-1951 Sion, Switzerland
[2] Hop Valais, Serv Med Interne, Ave Grand Champsec 86, CH-1951 Sion, Switzerland
来源
REVUE DE MEDECINE INTERNE | 2016年 / 37卷 / 09期
关键词
Oral anticoagulants; Acenocoumarol; Dabigatran; Rivaroxaban; NONVALVULAR ATRIAL-FIBRILLATION; ADVERSE DRUG-REACTIONS; ANTITHROMBOTIC THERAPY; WARFARIN USE; RISK; CARE; DABIGATRAN; PATIENT; STROKE; ACENOCOUMAROL;
D O I
10.1016/j.revmed.2015.10.355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. - The recently introduced oral direct anticoagulants (ODAs), presumably safer, and with comparable efficacy to the vitamin K antagonists (VKAs), may reshape the world of anticoagulation medicine. This study aimed to assess the prescription appropriateness of ODAs and VKAs at discharge from hospital. Methods. - We performed a one year retrospective study between August 2012 and July 2013 in the department of internal medicine of a regional hospital (HVs Sion) using Electronic Medical Records. All patients receiving an ODA were included and matched to a patient treated with a VKA. The appropriateness of prescription at discharge was defined by an adequate indication and dosing, the absence of contraindication, a minimal risk of drug-drug interactions and no major bleeding or venous thromboembolism during the hospitalization. The bleeding risk was evaluated with the HAS-BLED score when the indication was atrial fibrillation (AF). Results. - Out of the 44 patients included (22 with an ODA and 22 with a VILA), 38 received an appropriate prescription according to all criteria. Two patients had an inadequate dosing. A potential drug-drug interaction was detected in 3 patients receiving a VKA and in 1 patient receiving an ODA. No major contraindication was found, but a relative contraindication was discussed in 3 cases. The majority of patients receiving an ODA for an AF had a minor bleeding risk. Conclusion. - No significant difference was ascertained between the two groups regarding the appropriateness of prescription. Our results suggest that ODAs were cautiously used in our setting. (C) 2015 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:579 / 586
页数:8
相关论文
共 42 条
  • [1] Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals
    Albers, GW
    Yim, JM
    Belew, KM
    Bittar, N
    Hattemer, CR
    Phillips, BG
    Kemp, S
    Hall, EA
    Morton, DJ
    Vlasses, PH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (20) : 2311 - 2316
  • [2] Ang SY, 1998, J CLIN PHARM THER, V23, P97
  • [3] Bae JP, 2012, AM J MANAG CARE, V18, P139
  • [4] VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Bates, Shannon M.
    Greer, Ian A.
    Middeldorp, Saskia
    Veenstra, David L.
    Prabulos, Anne-Marie
    Vandvik, Per Olav
    [J]. CHEST, 2012, 141 (02) : E691S - E736S
  • [5] Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study
    Benard-Laribiere, Anne
    Miremont-Salame, Ghada
    Perault-Pochat, Marie-Christine
    Noize, Pernelle
    Haramburu, Francoise
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (01) : 106 - 111
  • [6] Warfarin for non-valvar atrial fibrillation: still underused in the 21st century?
    Bo, S
    Ciccone, G
    Scaglione, L
    Taliano, C
    Piobbici, M
    Merletti, F
    Pagano, G
    [J]. HEART, 2003, 89 (05) : 553 - 554
  • [7] Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
    Bo, Simona
    Valpreda, Susanna
    Scaglione, Luca
    Boscolo, Daniela
    Piobbici, Marina
    Bo, Mario
    Ciccone, Giovannino
    [J]. BMC PUBLIC HEALTH, 2007, 7 (1)
  • [8] Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
    Bodin, L
    Verstuyft, C
    Tregouet, DA
    Robert, A
    Dubert, L
    Funck-Brentano, C
    Jaillon, P
    Beaune, P
    Laurent-Puig, P
    Becquemont, L
    Loriot, MA
    [J]. BLOOD, 2005, 106 (01) : 135 - 140
  • [9] Briggs GG., 2009, DRUGS PREGNANCY LACT
  • [10] 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
    Camm, A. John
    Lip, Gregory Y. H.
    De Caterina, Raffaele
    Savelieva, Irene
    Atar, Dan
    Hohnloser, Stefan H.
    Hindricks, Gerhard
    Kirchhof, Paulus
    Bax, Jeroen J.
    Baumgartner, Helmut
    Ceconi, Claudio
    Dean, Veronica
    Deaton, Christi
    Fagard, Robert
    Funck-Brentano, Christian
    Hasdai, David
    Hoes, Arno
    Knuuti, Juhani
    Kolh, Philippe
    McDonagh, Theresa
    Moulin, Cyril
    Popescu, Bogdan A.
    Reiner, Zeljko
    Sechtem, Udo
    Sirnes, Per Anton
    Tendera, Michal
    Torbicki, Adam
    Vahanian, Alec
    Windecker, Stephan
    Vardas, Panos
    Al-Attar, Nawwar
    Alfieri, Ottavio
    Angelini, Annalisa
    Blomstrom-Lundqvist, Carina
    Colonna, Paolo
    De Sutter, Johan
    Ernst, Sabine
    Goette, Andreas
    Gorenek, Bulent
    Hatala, Robert
    Heidbuchel, Hein
    Heldal, Magnus
    Kristensen, Steen Dalby
    Le Heuzey, Jean-Yves
    Mavrakis, Hercules
    Mont, Lluis
    Filardi, Pasquale Perrone
    Ponikowski, Piotr
    Prendergast, Bernard
    Rutten, Frans H.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (21) : 2719 - 2747